Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Adenocarcinoma of Lung: early-phase trial registry

4 of 6 indexed Adenocarcinoma of Lung trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Adenocarcinoma of Lung: 6 US clinical trials tracked, 4 recruiting.

Adenocarcinoma of Lung is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is NewLink Genetics Corporation, running 1 of these trials.

Enrollment posture brief

Registry condition adenocarcinoma-of-lung

OPEN 4 | RECR 67% | LATE 0 | EARLY 5 | RANK #2866 | SPON 1

Nearest open-share peer: Agoraphobia (67% recruiting · 6 trials)

Adenocarcinoma of Lung (this)67%Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%
Open-enrollment share among volume-matched conditions near Adenocarcinoma of Lung

Adenocarcinoma of Lung lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Adenocarcinoma of Lung on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Adenocarcinoma of Lung is recruiting above its size-band peers.

    4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Adenocarcinoma of Lung research.

    NewLink Genetics Corporation accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Most Adenocarcinoma of Lung trials plan to enrol fewer than 100 people.

    Median target enrolment is 90 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.

  4. Adenocarcinoma of Lung research is mostly interventional.

    5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 23

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Named interventions

Most-linked intervention names on Adenocarcinoma of Lung records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Drug: Hyperacute Lung Cancer Cell Vaccine Biological
1 trials
Fulvestrant Combination
1 trials
Letrozole Combination
1 trials
LP-300 Drug
1 trials
DetermaRX Diagnostic test
1 trials
NovoTTF-200T System Device
1 trials
Cisplatin/pemetrexed or Carboplatin/pemetrexed Drug
1 trials
Durvalumab 1500 mg IV Drug
1 trials

US sites by state

Facility locations filed on Adenocarcinoma of Lung trials. A trial with sites in several states counts in each.

Texas 2 trials
California 2 trials
Virginia 1 trials
Tennessee 1 trials
Pennsylvania 1 trials
New York 1 trials
New Jersey 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Adenocarcinoma of Lung page

6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adenocarcinoma of Lung condition card totals 6 registered trials; most-linked intervention Drug: Hyperacute Lung Cancer Cell Vaccine; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.